Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
// Harish C. Pal 1 , Ariana C. Diamond 1 , Leah R. Strickland 1 , John C. Kappes 2 , Santosh K. Katiyar 1, 3 , Craig A. Elmets 1, 3 , Mohammad Athar 1, 2 , Farrukh Afaq 1, 3 1 Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama, USA 2 Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA 3 Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA Correspondence to: Farrukh Afaq, e-mail: farrukhafaq@uabmc.edu Keywords: melanoma, fisetin, sorafenib, EMT, invasion Received: August 23, 2015 Accepted: October 11, 2015 Published: October 26, 2015 ABSTRACT Melanoma is the most aggressive and deadly form of cutaneous neoplasm due to its propensity to metastasize. Oncogenic BRAF drives sustained activation of the BRAF/MEK/ERK (MAPK) pathway and cooperates with PI3K/AKT/mTOR (PI3K) signaling to induce epithelial to mesenchymal transition (EMT), leading to cell invasion and metastasis. Therefore, targeting these pathways is a promising preventive/therapeutic strategy. We have shown that fisetin, a flavonoid, reduces human melanoma cell invasion by inhibiting EMT. In addition, fisetin inhibited melanoma cell proliferation and tumor growth by downregulating the PI3K pathway. In this investigation, we aimed to determine whether fisetin can potentiate the anti-invasive and anti-metastatic effects of sorafenib in BRAF-mutated melanoma. We found that combination treatment (fisetin + sorafenib) more effectively reduced the migration and invasion of BRAF-mutated melanoma cells both in vitro and in raft cultures compared to individual agents. Combination treatment also effectively inhibited EMT as observed by a decrease in N-cadherin, vimentin and fibronectin and an increase in E-cadherin both in vitro and in xenograft tumors. Furthermore, combination therapy effectively inhibited Snail1, Twist1, Slug and ZEB1 protein expression compared to monotherapy. The expression of MMP-2 and MMP-9 in xenograft tumors was further reduced in combination treatment compared to individual agents. Bioluminescent imaging of athymic mice, intravenously injected with stably transfected CMV-luciferase-ires-puromycin.T2A.EGFP-tagged A375 melanoma cells, demonstrated fewer lung metastases following combination treatment versus monotherapy. Our findings demonstrate that fisetin potentiates the anti-invasive and anti-metastatic effects of sorafenib. Our data suggest that fisetin may be a worthy adjuvant chemotherapy for the management of melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulatory networks defining EMT during cancer initiation and progression
Craene, B. D., & Berx, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3447 · Cited by 2,487 · cited 1×
“This then leads to upregulated MMPs, which further activates EMT transcription factors in a feed-forward loop [53].”
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997) · Nature Biotechnology · doi:10.1038/nbt0997-871 · Cited by 1,977 · cited 1×
“The lentiviral vector, the packaging construct, and the VSV-G plasmid DNAs were cotransfected into 293T human embryo kidney cells to create infectious, replication defective, lentiviral vector-containing particles as described earlier [55].”
BrafV600E cooperates with Pten loss to induce metastatic melanoma
Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189
Wagle, N., Van Allen, E. M., Treacy, D. J., Frederick, D. T., Cooper, Z. A., Taylor-Weiner, A., Rosenberg, M., Goetz, E. M., Sullivan, R. J., Farlow, D. N., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0631 · Cited by 478 · cited 3×
“The 5-year survival rate for localized melanoma patients is over 90%; however, if the tumor metastasizes to distal organs the survival rate drops to ~10% [3].”
Cited by
Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential
Kashyap, D., Garg, V. K., Tuli, H. S., Yerer, M. B., Sak, K., Sharma, A. K., Kumar, M., Aggarwal, V., & Sandhu, S. S. (2019) · Biomolecules · doi:10.3390/biom9050174 · Cited by 285
“Furthermore, in addition to melanoma [18], fisetin was found to be effective in leukemia [165] and lymphoma cells through this pathway.”
BackgroundKrishnakumar, I. M., Jaja-Chimedza, A., Joseph, A., Balakrishnan, A., Maliakel, B., & Swick, A. (2022) · Journal of Nutritional Science · doi:10.1017/jns.2022.72 · Cited by 70
Melanoma Chemoprevention: Current Status and Future Prospects
Chhabra, G., Ndiaye, M. A., Garcia‐Peterson, L. M., & Ahmad, N. (2017) · Photochemistry and Photobiology · doi:10.1111/php.12749 · Cited by 51
Metadata
- Authors
- Pal, H. C., Diamond, A. C., Strickland, L. R., Kappes, J. C., Katiyar, S. K., Elmets, C. A., Athar, M., & Afaq, F.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-10-26
- Volume
- 7
- Issue
- 2
- Pages
- 1227-1241
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1827837756
- Cited by
- 79
- References
- 4
- FWCI
- 5.71
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.